Trials / Completed
CompletedNCT04596579
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,135 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | SARS-CoV-2 Antibody Analysis | 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months. |
| DIAGNOSTIC_TEST | Weck-cel Swab Collection | A Weck-cel swab will be used to collect secretions from the mucosal epithelium |
| BEHAVIORAL | Web Based Questionnaire | A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications. |
Timeline
- Start date
- 2020-10-17
- Primary completion
- 2021-07-25
- Completion
- 2021-07-25
- First posted
- 2020-10-22
- Last updated
- 2022-10-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04596579. Inclusion in this directory is not an endorsement.